Prevalence and Determinants of Liver Disease in Relatives of Italian Patients With Advanced MASLD
Clinical Gastroenterology and Hepatology · 2024
DOI: 10.1016/j.cgh.2023.12.033 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024. Verfasst von Serena Pelusi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine Lab, Biological Resource Center - Transfusion Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Fatty Liver. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Medicines Initiative 2 (IMI) / Horizon 2020, European Union Horizon 2020 (REVEAL), European Union Horizon Europe (Genial).
Abstract (Originalsprache)
BACKGROUND & AIMS: Metabolic dysfunction associated steatotic liver disease (MASLD) has a strong genetic component. The aim of this study was to examine noninvasively the prevalence of MASLD and of advanced fibrosis in relatives of patients with advanced MASLD and the risk factors for liver involvement, with a focus on the contribution of common genetic risk variants. METHODS: We prospectively enrolled 98 consecutive probands with advanced fibrosis and/or hepatocellular carcinoma caused by MASLD and 160 nontwin first-degree relatives noninvasively screened for MASLD and advanced fibrosis at 4 Italian centers. We evaluated common genetic determinants and polygenic risk scores of liver disease. RESULTS: Among relatives, prevalence of MASLD was 56.8% overall, whereas advanced fibrosis was observed in 14.4%. At multivariable analysis in relatives, MASLD was associated with body mass index (odds ratio [OR], 1.31 [1.18-1.46]) and tended to be associated with diabetes (OR, 5.21 [0.97-28.10]), alcohol intake (OR, 1.32 [0.98-1.78]), and with female sex (OR, 0.54 [0.23-1.15]), whereas advanced fibrosis was associated with diabetes (OR, 3.13 [1.16-8.45]) and nearly with body mass index (OR, 1.09 [1.00-1.19]). Despite that the PNPLA3 risk variant was enriched in probands (P = .003) and overtransmitted to relatives with MASLD (P = .045), evaluation of genetic risk variants and polygenic risk scores was not useful to guide noninvasive screening of advanced fibrosis in relatives. CONCLUSIONS: We confirmed that about 1 in 7 relatives of patients with advanced MASLD has advanced fibrosis, supporting clinical recommendations to perform family screening in this setting. Genetic risk variants contributed to liver disease within families but did not meaningfully improve fibrosis risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision Medicine Lab, Biological Resource Center - Transfusion Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy.
- Department of Health promotion, Mother and Childcare, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy.
- Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Clinica Medica-Liver Unit, Department of Medicine, University of Udine, Udine, Italy; Italian Liver Foundation, Area Science Park, Basovizza-Trieste, Italy.
- Precision Medicine Lab, Biological Resource Center - Transfusion Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, Università degli Stu…
Förderung
- Innovative Medicines Initiative 2 (IMI) / Horizon 2020
- European Union Horizon 2020 (REVEAL)
- European Union Horizon Europe (Genial)
- Ministero dell'Istruzione dell'Universita e della Ricerca
- European Commission
- Horizon 2020
- Ministero della Salute
- ERC
Zitieren
APA
Pelusi, S., Ronzoni, L., Rondena, J., Rosso, C., Pennisi, G., Dongiovanni, P., Margarita, S., Carpani, R., Soardo, G., Prati, D., Cespiati, A., Petta, S., Bugianesi, E., & Valenti, L. (2024). Prevalence and Determinants of Liver Disease in Relatives of Italian Patients With Advanced MASLD. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.12.033
Vancouver
Pelusi S, Ronzoni L, Rondena J, Rosso C, Pennisi G, Dongiovanni P, et al. Prevalence and Determinants of Liver Disease in Relatives of Italian Patients With Advanced MASLD. Clinical Gastroenterology and Hepatology. 2024. doi:10.1016/j.cgh.2023.12.033
BibTeX
@article{Pelusi2024,
author = {Pelusi, Serena and Ronzoni, Luisa and Rondena, Jessica and Rosso, Chiara and Pennisi, Grazia and Dongiovanni, Paola and Margarita, Sara and Carpani, Rossana and Soardo, Giorgio and Prati, Daniele and Cespiati, Annalisa and Petta, Salvatore and Bugianesi, Elisabetta and Valenti, Luca},
title = {Prevalence and Determinants of Liver Disease in Relatives of Italian Patients With Advanced MASLD},
journal = {Clinical Gastroenterology and Hepatology},
year = {2024},
doi = {10.1016/j.cgh.2023.12.033}
}
EUVIMED